Novel protein offers 10-day dosing of factor VIII therapy in haemophilia A

Treatment of haemophilia A may be revolutionised by a novel engineered protein that extends the half-life of Factor VIII four-fold by decoupling it from endogenous von Willebrand factor (VWF). US researchers says extended half life Factor VII products have already improved therapy of haemophilia A by allowing for twice weekly injections, but they say a ...

Already a member?

Login to keep reading.

© 2021 the limbic